Based on the Medpace Holdings Inc stock forecast from 8 analysts, the average analyst target price for Medpace Holdings Inc is USD 410.33 over the next 12 months. Medpace Holdings Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Medpace Holdings Inc is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Medpace Holdings Inc’s stock price was USD 341.82. Medpace Holdings Inc’s stock price has changed by +2.08% over the past week, -3.15% over the past month and +23.46% over the last year.
No recent analyst target price found for Medpace Holdings Inc
No recent average analyst rating found for Medpace Holdings Inc
Company Overview Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio. Read Less
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It pr...Read More
Frequently Asked Questions About Medpace Holdings Inc (MEDP) Stock
Based on ratings from 8 analysts Medpace Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 8 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on MEDP's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for MEDP is USD 410.33 over the next 12 months. The maximum analyst target price is USD 469 while the minimum anlayst target price is USD 336.
MEDP stock's Price/Earning ratio is 28.01.
Our analysis grades MEDP stock's Price / Earning ratio at F. This means that MEDP stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this MEDP may be a overvalued for its sector.
The last closing price of MEDP's stock was USD 341.82.
The most recent market capitalization for MEDP is USD 9.93B.
Based on targets from 8 analysts, the average taret price for MEDP is projected at USD 410.33 over the next 12 months.
This means that MEDP's stock price may go up by +20.04% over the next 12 months.
We can't find any ETFs which contains Medpace Holdings Inc's stock.
As per our most recent records Medpace Holdings Inc has 5,900 Employees.
Medpace Holdings Inc's registered address is 5375 Medpace Way, Cincinnati, OH, United States, 45227.
You can get more information about it from Medpace Holdings Inc's website at https://www.medpace.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Medpace Holdings Inc (MEDP) Stock
Based on ratings from 8 analysts Medpace Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 8 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on MEDP's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for MEDP is USD 410.33 over the next 12 months. The maximum analyst target price is USD 469 while the minimum anlayst target price is USD 336.
MEDP stock's Price/Earning ratio is 28.01.
Our analysis grades MEDP stock's Price / Earning ratio at F. This means that MEDP stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this MEDP may be a overvalued for its sector.
The last closing price of MEDP's stock was USD 341.82.
The most recent market capitalization for MEDP is USD 9.93B.
Based on targets from 8 analysts, the average taret price for MEDP is projected at USD 410.33 over the next 12 months.
This means that MEDP's stock price may go up by +20.04% over the next 12 months.
We can't find any ETFs which contains Medpace Holdings Inc's stock.
As per our most recent records Medpace Holdings Inc has 5,900 Employees.
Medpace Holdings Inc's registered address is 5375 Medpace Way, Cincinnati, OH, United States, 45227.
You can get more information about it from Medpace Holdings Inc's website at https://www.medpace.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MEDP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
